YUHSpace

BROWSE

YUHSpace1. College of Medicine (의과대학)Dept. of Obstetrics and Gynecology (산부인과학교실)

1. Journal Papers

This table browses all dspace content
Issue DateTitleJournal Title
2024A randomized phase II study of secondary cytoreductive surgery in patients with relapsed ovarian cancer who have progressed on a PARP inhibitor as first-line maintenance therapy: the SOCCER-P study (KGOG 3067/JGOG 3036/APGOT-OV11) INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
2024Mismatch repair, p53, and L1 cell adhesion molecule status influence the response to chemotherapy in advanced and recurrent endometrial cancer BMC CANCER
2025The Association Between Location of BRCA Mutation and Efficacy of PARP Inhibitor as a Frontline Maintenance Therapy in Advanced Epithelial Ovarian Cancer CANCERS
2025Exploring the characteristics of immortalized human ovarian surface epithelial cell lines HELIYON
2024The 2024 Guidelines for Osteoporosis - Korean Society of Menopause: Part II Journal of Menopausal Medicine
2024The 2024 Guidelines for Osteoporosis - Korean Society of Menopause: Part II Journal of Menopausal Medicine
2024Clinicopathological Features and Oncological Outcomes of Germline Partner and Localizer of Breast Cancer 2-Mutated Breast Cancer in KoreaJOURNAL OF BREAST CANCER
2024Changes in the tumor immune microenvironment during disease progression in clear cell ovarian cancerINTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
2024Prediction of final pathology depending on preoperative myometrial invasion and grade assessment in low-risk endometrial cancer patients: A Korean Gynecologic Oncology Group ancillary study PLOS ONE
2025Loss of E-cadherin Activates EGFR-MEK/ERK Signaling, Promoting Cervical Cancer Progression CANCER GENOMICS & PROTEOMICS
2025Handgrip strength and diabetes in postmenopausal women: insights from the Korean National Health and Nutrition Examination Survey 2014-2019MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY
2024Reply to: Comments on "Randomized, two-arm, non-comparative phase 2 study of olaparib plus cediranib or durvalumab in HRR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045INTERNATIONAL JOURNAL OF CANCER
2024Postoperative Outcomes of Ovarian Preserving Surgery in Premenopausal Women With Adnexal TorsionOBSTETRICAL & GYNECOLOGICAL SURVEY
2025PM exposure during pregnancy affects childhood asthma via placental epigenetic changes: Neuronal differentiation and proliferation and Notch signaling pathwaysENVIRONMENTAL POLLUTION
2024Chemotherapy response score no longer predicts survival outcomes in high-grade serous ovarian cancer patients with BRCA mutation and/or maintenance therapyJOURNAL OF GYNECOLOGIC ONCOLOGY
2024From the Beginning of the Korean Gynecologic Oncology Group to the Present and Next Steps CANCERS
2024Pembrolizumab or Placebo With Chemoradiotherapy Followed by Pembrolizumab or Placebo for Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): A Randomized, Double-Blind, Phase 3 Clinical TrialOBSTETRICAL & GYNECOLOGICAL SURVEY
2024Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trialLANCET
2024Unique immune characteristics and differential anti-PD-1-mediated reinvigoration potential of CD8 + TILs based on BRCA1/2 mutation status in epithelial ovarian cancers JOURNAL FOR IMMUNOTHERAPY OF CANCER
2024Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical CancerNEW ENGLAND JOURNAL OF MEDICINE
1234567891011 84

Recent Submissions

  • License
    sherpa_romeo
    sherpa_juliet

OAK

DSpace Software Copyright © 2002-2017 Duraspace Yonsei University Medical Library All right Reserves. / TEL:02-2228-2915 /
YUHSpace는 국립중앙도서관 OAK 보급사업으로 구축되었습니다.

Browse

Links